Public market insider buying at Neovasc (NVCN)

Public market insider buying at Neovasc (T:NVCN)

William Reed Little, a Senior Officer, acquired 150,000 Common Shares on a direct ownership basis at a price of $0.670USD on December 9th, 2021. This represents a $127,635 investment into the company's shares and an account share holdings change of greater than 100%.

Fredericus Colen, CEO, acquired 44,600 Common Shares on a direct ownership basis at a price of $0.560USD on December 20th, 2021. This represents a $32,324 investment into the company's shares and an account share holdings change of 28.7%.

Neovasc is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Neovasc Inc. is a Canada-based specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's products include the Neovasc ReducerTM (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle and the TiaraTM (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.